文献速递肺外科

慢性肺曲霉病手术治疗的临床结局

Clinical outcomes of patients with chronic pulmonary aspergillosis managed surgically.
PubMed 文献 · Eur J Cardiothorac Surg · 2020-01-01

该研究回顾性分析了2007-2018年英国曼彻斯特国家曲霉病中心61例接受手术治疗的慢性肺曲霉病(CPA)患者,发现手术总体结局良好,但41%患者术后中位26个月复发,术前或围手术期抗真菌治疗可降低复发风险,术后监测曲霉IgG抗体有助于发现复发。

要点

  • CPA手术适应证包括抗真菌治疗失败(51%)和疑似肺癌(38%)。
  • 术后复发率41%,中位复发时间26个月,3年内复发率高于3-10年。
  • 术前或术前术后联合抗真菌治疗是复发的保护因素。

核心结论

  • 在这组经过选择的CPA患者中,手术治疗取得了良好的结局,但术后复发常见,抗真菌治疗可减少复发。

研究设计与样本

  • 回顾性队列研究,纳入2007-2018年英国曼彻斯特国家曲霉病中心接受手术治疗的61例CPA患者(男28例,女33例)。

主要发现

  • 手术方式包括肺叶切除64%(n=39)、楔形切除28%(n=17)、肺段切除3例、全肺切除3例和胸膜剥脱2例。
  • 25例(41%)患者复发,复发时间中位数26个月(标准差24.8个月)。
  • 术后3年内复发率为33%(n=20),高于术后3-10年的8%(n=5)。
  • 术前抗真菌治疗(P=0.002)或术前术后均抗真菌治疗(P=0.005)对复发具有保护作用。
  • 12例患者随访结束时曲霉IgG滴度中位数低于复发时(67 vs 126 mg/l)(P=0.016)。

关键数值与推荐

  • 术前抗真菌治疗与较低复发风险相关(P=0.002)。
  • 术前和术后均进行抗真菌治疗与较低复发风险相关(P=0.005)。

临床怎么用

  • 对于CPA患者,手术是有效的治疗选择,但应重视术前准确诊断和围手术期抗真菌治疗以降低复发风险。
  • 术后应监测曲霉IgG抗体滴度,其升高可能提示复发。

局限性

  • 回顾性研究,样本量较小(61例),来自单中心,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Surgical resection is one treatment modality for chronic pulmonary aspergillosis (CPA), and sometimes a preoperative presumption of lung cancer turns out to be CPA. We have audited our surgical experience with regard to risk factors for relapse, and the value of postoperative monitoring of Aspergillus-immunogolubulin G (IgG) titres. METHODS: All patients with CPA surgically treated at National Aspergillosis Centre (NAC), Manchester, UK (2007-2018), were retrospectively evaluated. Surgical procedures, underlying disorders, Aspergillus-IgG titres (ImmunoCap) and antifungal therapy were evaluated for symptom control, operative complications, CPA relapse and mortality. RESULTS: A total of 61 patients with CPA (28 males, 33 females) were operated on primarily for antifungal therapy failure (51%, n = 31) and presumed lung malignancies (38%, n = 23). Procedures included lobectomy (64%, n = 39), wedge resection (28%, n = 17), segmentectomy (n = 3), pneumonectomy (n = 3) and decortication (n = 2). Overall, 25 (41%) patients relapsed, 26 months (standard deviation: 24.8 months) after surgery. Antifungal therapy before surgery (P = 0.002) or both before and after surgery (P = 0.005) were protective for relapse. The relapse rate within 3 years after surgery (33%, n = 20) was higher than the 3-10 years after surgery (8%, n = 5). At the end of follow-up, the median Aspergillus-IgG titre was lower than at relapse in 12 patients (67 vs 126 mg/l) (P = 0.016). CONCLUSIONS: Surgery in these selected patients with CPA resulted in favourable outcomes. Relapse is common after surgical treatment of CPA but can be minimized with antifungal therapy, emphasizing the importance of an accurate diagnosis prior to surgery.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Setianingrum F, Rautemaa-Richardson R, Shah R, et al. Clinical outcomes of patients with chronic pulmonary aspergillosis managed surgically. Eur J Cardiothorac Surg. 2020. PMID: 32386208. doi:10.1093/ejcts/ezaa137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。